EU Blesses Merck's $41B Schering-Plough Deal

Law360, New York (October 23, 2009, 2:37 PM EDT) -- EU antitrust regulators have cleared Merck & Co.’s proposed $41.1 billion acquisition of Schering-Plough Corp., a move that will make it the second-largest prescription drug company in the world.

The European Commission said Friday that the proposed deal would not “significantly impede effective competition” in Europe.

The New Jersey-based companies already have a working relationship based on a joint venture they entered into a few years ago for marketing and studying the cholesterol drugs Vytorin and Zetia. The union of Merck and Schering would form one...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.